Hermle, Leo; Kraehenmann, Rainer (2017). "Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology". Current Topics in Behavioral Neurosciences. 36: 313–332. doi:10.1007/7854_2016_460. ISBN978-3-662-55878-2. PMID28444578.
Wohlfarth A, Weinmann W (May 2010). "Bioanalysis of new designer drugs". Bioanalysis. 2 (5): 965–79. doi:10.4155/bio.10.32. PMID21083227.
Preller, Katrin H.; Vollenweider, Franz X. (2016). "Phenomenology, Structure, and Dynamic of Psychedelic States". In Adam L. Halberstadt; Franz X. Vollenweider; David E. Nichols (eds.). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 221–256. doi:10.1007/7854_2016_459. ISBN978-3-662-55878-2. PMID28025814.
R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID16826400. S2CID7845214.
Johnson, Matthew W.; Hendricks, Peter S.; Barrett, Frederick S.; Griffiths, Roland R. (2019). "Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function". Pharmacology & Therapeutics. 197: 83–102. doi:10.1016/j.pharmthera.2018.11.010. PMID30521880. S2CID54467870.
Nicholson KL, Hayes BA, Balster RL (September 1999). "Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys". Psychopharmacology. 146 (1): 49–59. doi:10.1007/s002130051087. PMID10485964. S2CID28576850.
Price, William A.; Giannini, Matthew C.; Giannini, A. James (1984). "Antidotal Strategies in Phencyclidine Intoxication". The International Journal of Psychiatry in Medicine. 14 (4): 315–21. doi:10.2190/KKAW-PWGF-W7RQ-23GN. S2CID72401949.
Beaver, Kathleen M; Gavin, Thomas J (1998). "Treatment of acute anticholinergic poisoning with physostigmine". The American Journal of Emergency Medicine. 16 (5): 505–507. doi:10.1016/S0735-6757(98)90003-1. PMID9725967.
Francom P, Andrenyak D, Lim HK, Bridges RR, Foltz RL, Jones RT (January–February 1988). "Determination of LSD in urine by capillary column gas chromatography and electron impact mass spectrometry". Journal of Analytical Toxicology. 12 (1): 1–8. doi:10.1093/jat/12.1.1. PMID3352236.
Halpern, John H.; Lerner, Arturo G.; Passie, Torsten (2018). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. 36: 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Shalit N, Rehm J, Lev-Ran S (2019). "Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III". Addictive Behaviors. 89: 35–43. doi:10.1016/j.addbeh.2018.09.020. PMID30245407. S2CID52821352.
Vollenweider FX, Geyer MA (November 2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. PMID11750795. S2CID230298.
Aghajanian GK, Marek GJ (March 2000). "Serotonin model of schizophrenia: emerging role of glutamate mechanisms". Brain Research. Brain Research Reviews. 31 (2–3): 302–12. doi:10.1016/S0165-0173(99)00046-6. PMID10719157. S2CID13040014.
Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (November 2003). "Diverse psychotomimetics act through a common signaling pathway". Science. 302 (5649): 1412–5. Bibcode:2003Sci...302.1412S. doi:10.1126/science.1089681. PMID14631045. S2CID84901005.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (November 2005). "Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers". Pharmacopsychiatry. 38 (6): 301–11. doi:10.1055/s-2005-916185. PMID16342002. S2CID28653940.
drugabuse.gov
archives.drugabuse.gov
Glennon RA. Classical drugs: an introductory overview. In Lin GC and Glennon RA (eds). Hallucinogens: an updateArchived 23 July 2015 at the Wayback Machine. National Institute on Drug Abuse: Rockville, MD, 1994.
Hermle, Leo; Kraehenmann, Rainer (2017). "Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology". Current Topics in Behavioral Neurosciences. 36: 313–332. doi:10.1007/7854_2016_460. ISBN978-3-662-55878-2. PMID28444578.
Wohlfarth A, Weinmann W (May 2010). "Bioanalysis of new designer drugs". Bioanalysis. 2 (5): 965–79. doi:10.4155/bio.10.32. PMID21083227.
Preller, Katrin H.; Vollenweider, Franz X. (2016). "Phenomenology, Structure, and Dynamic of Psychedelic States". In Adam L. Halberstadt; Franz X. Vollenweider; David E. Nichols (eds.). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 221–256. doi:10.1007/7854_2016_459. ISBN978-3-662-55878-2. PMID28025814.
R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID16826400. S2CID7845214.
Johnson, Matthew W.; Hendricks, Peter S.; Barrett, Frederick S.; Griffiths, Roland R. (2019). "Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function". Pharmacology & Therapeutics. 197: 83–102. doi:10.1016/j.pharmthera.2018.11.010. PMID30521880. S2CID54467870.
Pender JW (October 1972). "Dissociative anesthesia". California Medicine Some Dissociatives Have General Depressant Effects as Well, Which is Why Doctors Prescribe Them to Sedate Patients Who Are in Pain or to Help Maintain General Anesthesia During an Operation. Common Dissociative Drugs Include: PCP (Phencyclidine). 117 (4): 46–7. PMC1518731. PMID18730832.
Simeon D, Gross S, Guralnik O, Stein DJ, Schmeidler J, Hollander E (August 1997). "Feeling unreal: 30 cases of DSM-III-R depersonalization disorder". The American Journal of Psychiatry. 154 (8): 1107–13. doi:10.1176/ajp.154.8.1107. PMID9247397. S2CID10128404.
Nicholson KL, Hayes BA, Balster RL (September 1999). "Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys". Psychopharmacology. 146 (1): 49–59. doi:10.1007/s002130051087. PMID10485964. S2CID28576850.
Beaver, Kathleen M; Gavin, Thomas J (1998). "Treatment of acute anticholinergic poisoning with physostigmine". The American Journal of Emergency Medicine. 16 (5): 505–507. doi:10.1016/S0735-6757(98)90003-1. PMID9725967.
Francom P, Andrenyak D, Lim HK, Bridges RR, Foltz RL, Jones RT (January–February 1988). "Determination of LSD in urine by capillary column gas chromatography and electron impact mass spectrometry". Journal of Analytical Toxicology. 12 (1): 1–8. doi:10.1093/jat/12.1.1. PMID3352236.
Halpern, John H.; Lerner, Arturo G.; Passie, Torsten (2018). "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD". Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. 36: 333–360. doi:10.1007/7854_2016_457. ISBN978-3-662-55878-2. PMID27822679.
Shalit N, Rehm J, Lev-Ran S (2019). "Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III". Addictive Behaviors. 89: 35–43. doi:10.1016/j.addbeh.2018.09.020. PMID30245407. S2CID52821352.
Vollenweider FX, Geyer MA (November 2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. PMID11750795. S2CID230298.
Aghajanian GK, Marek GJ (March 2000). "Serotonin model of schizophrenia: emerging role of glutamate mechanisms". Brain Research. Brain Research Reviews. 31 (2–3): 302–12. doi:10.1016/S0165-0173(99)00046-6. PMID10719157. S2CID13040014.
Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (November 2003). "Diverse psychotomimetics act through a common signaling pathway". Science. 302 (5649): 1412–5. Bibcode:2003Sci...302.1412S. doi:10.1126/science.1089681. PMID14631045. S2CID84901005.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (November 2005). "Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers". Pharmacopsychiatry. 38 (6): 301–11. doi:10.1055/s-2005-916185. PMID16342002. S2CID28653940.
Pender JW (October 1972). "Dissociative anesthesia". California Medicine Some Dissociatives Have General Depressant Effects as Well, Which is Why Doctors Prescribe Them to Sedate Patients Who Are in Pain or to Help Maintain General Anesthesia During an Operation. Common Dissociative Drugs Include: PCP (Phencyclidine). 117 (4): 46–7. PMC1518731. PMID18730832.
R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID16826400. S2CID7845214.
Johnson, Matthew W.; Hendricks, Peter S.; Barrett, Frederick S.; Griffiths, Roland R. (2019). "Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function". Pharmacology & Therapeutics. 197: 83–102. doi:10.1016/j.pharmthera.2018.11.010. PMID30521880. S2CID54467870.
Simeon D, Gross S, Guralnik O, Stein DJ, Schmeidler J, Hollander E (August 1997). "Feeling unreal: 30 cases of DSM-III-R depersonalization disorder". The American Journal of Psychiatry. 154 (8): 1107–13. doi:10.1176/ajp.154.8.1107. PMID9247397. S2CID10128404.
Herling S, Coale EH, Hein DW, Winger G, Woods JH (1981). "Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrorphan in the pigeon". Psychopharmacology. 73 (3): 286–91. doi:10.1007/BF00422419. hdl:2027.42/46423. PMID6787651. S2CID2369250.
Nicholson KL, Hayes BA, Balster RL (September 1999). "Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys". Psychopharmacology. 146 (1): 49–59. doi:10.1007/s002130051087. PMID10485964. S2CID28576850.
Price, William A.; Giannini, Matthew C.; Giannini, A. James (1984). "Antidotal Strategies in Phencyclidine Intoxication". The International Journal of Psychiatry in Medicine. 14 (4): 315–21. doi:10.2190/KKAW-PWGF-W7RQ-23GN. S2CID72401949.
Shalit N, Rehm J, Lev-Ran S (2019). "Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III". Addictive Behaviors. 89: 35–43. doi:10.1016/j.addbeh.2018.09.020. PMID30245407. S2CID52821352.
Vollenweider FX, Geyer MA (November 2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. PMID11750795. S2CID230298.
Aghajanian GK, Marek GJ (March 2000). "Serotonin model of schizophrenia: emerging role of glutamate mechanisms". Brain Research. Brain Research Reviews. 31 (2–3): 302–12. doi:10.1016/S0165-0173(99)00046-6. PMID10719157. S2CID13040014.
Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (November 2003). "Diverse psychotomimetics act through a common signaling pathway". Science. 302 (5649): 1412–5. Bibcode:2003Sci...302.1412S. doi:10.1126/science.1089681. PMID14631045. S2CID84901005.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (November 2005). "Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers". Pharmacopsychiatry. 38 (6): 301–11. doi:10.1055/s-2005-916185. PMID16342002. S2CID28653940.
Glennon RA. Classical drugs: an introductory overview. In Lin GC and Glennon RA (eds). Hallucinogens: an updateArchived 23 July 2015 at the Wayback Machine. National Institute on Drug Abuse: Rockville, MD, 1994.